SlideShare a Scribd company logo
MANAGEMENT OF
ACUTE GRAFT VERSUS HOST
DISEASE (GVHD)
Mahmoud A. Hashim Ahmed Khalaf
Visiting Students
UAB School of Medicine
Hem-Onc Department
Bone Marrow Transplantation Unit
DEFINITION
 Multisystem Disorders due to immune
reaction caused by transplanted cells from a
non-identical donor (the graft) that
recognize recipient cells
(the host) as foreign, thus disease is caused
in the recipient organs.
 It can be fatal in up to 15% of HSCT
recipients.
PATHOGENESIS
CLASSIFICATION
 Patients with GVHD are sub classified based upon the timing of presentation and the features
present:
 Classic acute GVHD
 Cases present within 100 days of hematopoietic cell transplant (HCT).
 Shows features of acute GVHD.
 Diagnostic features of chronic GVHD are absent.
 Persistent, recurrent, late onset acute GVHD
 Cases present greater than 100 days post-HCT.
 Shows features of acute GVHD.
 Diagnostic features of chronic GVHD are absent.
 Classic chronic GVHD
 Cases may present at any time post-HCT.
 Diagnostic features of chronic GVHD are present.
 There are no features of acute GVHD.
 Overlap syndrome “Acute on Chronic GVHD”
 Cases may present at any time post-HCT .
 Shows features of both chronic GVHD and acute GVHD.
CLINICAL MANIFESTATIONS AND GRADING
I. Maculopapular rash. “ 1st and most common symptom”
II. GI Symptoms “ 2nd commonest symptoms”
 Diarrhea with or without Abd. Pain.
 Persistent nausea and/or emesis.
III. Jaundice
“Glucksberg Criteria”
Overall Grading of
Acute GVHD
If Karnofsky Performance <30%, then Grade 4
DIAGNOSES
I. Clinical Evaluation
The diagnosis of aGvHD is
predominantly based on clinical
findings.
II. Histological Tests
A. Skin Biopsy is important in absence
of the classic symptoms.
 Skin biopsy was not found to be
useful in predicting severity of
disease.
B. Rectosigmoid Biopsy was found to
be the most informative.
C. Transjugular liver biopsy can show
Endothelialitis, Lymphocytic
infiltration of the portal area,
pericholangitis and Bile duct
obstruction.
III. Imaging
 upper GI endoscopy as well as lower
endoscopic biopsy may show
Luminal Dilatation and Thckening of
small bowel wall.
IV. Biomarkers
 There are many candidate biomarkers
but none are ready for clinical
application.
MANAGEMENT
 The choice of initial therapy for patients with acute graft-verus-host
disease (GVHD) depends upon :
Overall grading of Acute GVHD.
Grade 1 GVHD Management
A. Topical steroids are the most commonly used skin-directed
therapy for acute GVHD.
B. Antihistamines may be used as supportive therapy for
patients with pruritus.
C. In Resistant grade 1 aGVHD,
Topical Tacrolimus may be useful.
D. Optimizing prophylactic agents
When acute GVHD of any grade develops, to ensure a
therapeutic level.
For those no longer receiving prophylaxis, the prior
prophylactic agent should be restarted again.
GRADE 2-4 GVHD
 Patients with grade 2-4 disease are likely
to require addition of Systemic agents to
achieve a response and Optimizing
prophylactic calcineurin inhibitors
agents.
A. First Line of Treatment:
Corticosteroids
 Most centres used 2 mg/kg /day of
methylprednisolone to be the standard
primary dose.
 Oral beclomethasone, a non-
absorbable glucocorticoid, is added
for most patients with GI involvement.
 Topical steroids can be added for
further control of Skin lesions.
 Steroids are continued for several weeks in
responders and then gradually tapered over
a period of several months.
 Patients who shows progression of disease
by day 5 or non-response by day 7 are
considered to have corticosteroid resistance.
 Use of Steroids results in complete response
rates ranging from 25 to 40 %.
HOW TO TAPER THE STEROIDS AFTER INITIAL RESPONSE?
Conclusion
I. Tapering of steroid doses should begin as soon as GVHD
manifestations show major improvement.
II. Inappropriately rapid taper rates carry a risk of GVHD
exacerbation or recurrence, while inappropriately slow taper rates
increase the risk of steroid-related complications.
III. Doses should be gradual reduced 0.2 mg/kg/day every 3–5 days,
after prednisone doses are decreased to less than 20–30 mg/day,
slower tapering rate is required.
B. Second Line of Treatment:
 Given in Patients who fail to respond
to
2 mg/kg/day Methylprednisolone for
5 d or progressive symptoms after 72
h.
 There is nostrong comparative data
showing superior efficacy for any
particular agent over others, so the
choice of a second-line regimen
should be guided by
1. Considerations of potential toxicity,
interactions with other agents
2. Expense
3. The familiarity of the physician with
the agent
4. The prior experience of the
physician
 Includes:
1. Mycophenolate mofetil (MMF)
2. Etanercept “ Anti TNF Antibodies”
3. Pentostatin
4. Sirolimus
5. Basiliximab
6. Extracorporeal Photopheresis
I. MYCOPHENOLATE MOFETIL (MMF)
Mechanism of Action:
I. MMF is a prodrug of mycophenolic acid (MPA), an inhibitor of inosine monophosphate
dehydrogenase (IMPDH).
 This is the rate-limiting enzyme in de novo synthesis of guanosine nucleotides.
 T- and B-lymphocytes are more dependent on this pathway than other cell types are.
II. MPA can induce apoptosis of activated T-lymphocytes.
III. MMF dose in Adults is 2 gm/kg/day.
 Side Effects
 Dose related Cytopenia and gastrointestinal toxicity.
 Moderate High possibility of Viral reactivation.
II. ETANERCEPT
 A recombinant human TNF-alpha
receptor fusion protein.
 Given SC at a dose of 0.4 mg/kg
per dose, Twice/ week.
(maximum dose, 25 mg/week).
 Mechanism
 A purine analog, a potent inhibitor
of adenosine deaminase.
 T and NK Cells Death occurs due to
accumulation of 2-deoxyadenosine
5-triphosphate.
 Dose: 1.5 mg/m2 IV /day for three
days.
 Pentostatin should be used with
caution in patients with
renal insufficiency.
 A 50 % dose reduction has been
suggested for patients with an
estimated creatinine clearance of
30 to 50 mL/min/1.73 m2
III. Pentostatin
IV. SIROLIMUS
(RAPAMYCIN)
 Mechanism
 Exerts its immunosuppressive effect through
inhibition of mTOR.
 Loading dose of 6 mg/m2 followed by a daily
dose of 3 mg/m2 daily for 13 days .
 At a dose of 4 -5 mg/m2 without a loading
dose for 14 days.
 Reversible cytopenia, hypertriglyceridemia,
and nephrotoxicity (HUS) and neurotoxicity
when combined with calcineurin inhibitors.
 The use of Sirolimus has also been associated
with sinusoidal obstruction syndrome (SOS)
following conditioning regimens especially,
Busulfan.
 Mechanism
 Humanized monoclonal antibodies
directed against the interleukin-2
receptor leading to prevention of T-
cell proliferation.
V. BASILIXIMAB
VI. DENILEUKIN
DIFTITOX
 Mechanism
Recombinant fusion molecule of
human IL-2 and diphtheria toxin
that binds to the IL-2R-α and
triggers apoptosis in activated T
cells.
VII.EXTRACORPOREAL PHOTOPHERESIS
 Infusion of ultraviolet-A irradiated
autologous peripheral lymphocytes
which have been collected by
apheresis and incubated with 8-
methoxypsoralen.
 ECP induces apoptosis of all
leucocytes (including activatedn T-
cells) within 24 h of return.
 Several studies have suggested that
ECP may have a role in the treatment
of acute GVHD.
 Better results are expected in patients
with disease limited to the skin.
 Side effects is mild including
hypotension, fevers and reduced
hemoglobin level.
GvHD
Diagnosing
and Grading
Grade 1
Topical
steroid
Grade 2-4
First Line
Systemic
steroids
2mg/kg/day
Second Line
CONCLUSION
MMF
Etanercept
Pentostatin
Sirolimus
Extracorporeal
Photopheresis
BASILIXIMAB
REFERENCES
I. Advances in graft-versus-host disease biology and therapy,2013,
Bruce R. Blazar, William J. Murphy, and Mehrdad Abedi
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3552454/
II. Diagnosis and management of acute graft-versus-host disease,
2012, Fiona L. Dignan et al.
http://www.bcshguidelines.com/documents/bjh_9129_Rev_EV.pdf
III. First and Second-Line Systemic Treatment of Acute Graft-versus-
host Disease: Recommendations of the American Society of Blood
and Marrow Transplantation, Paul J. Martin et al.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3404151/
IV. Management of Acute GVHD, Uptodate.com
V. Extracorporeal photopheresis in the management of graft-versus-
host disease, Bredeson C et al.
http://www.ncbi.nlm.nih.gov/pubmed/24764713
Management of acute graft versus host disease

More Related Content

What's hot

Stem cell transplantation
Stem cell transplantationStem cell transplantation
Stem cell transplantation
DrAyush Garg
 
Immunotherapy for cancer
Immunotherapy for cancerImmunotherapy for cancer
Immunotherapy for cancer
Nethravathi Siri
 
Hsct copy
Hsct   copyHsct   copy
Hsct copy
Nilesh Kucha
 
Targeted Therapies in Cancer
Targeted Therapies in CancerTargeted Therapies in Cancer
Targeted Therapies in Cancer
Himadri Nath
 
Anthracyclines
Anthracyclines Anthracyclines
Anthracyclines
Dr. Chinmayee Agrawal
 
Stem cell transplant
Stem cell transplantStem cell transplant
Stem cell transplant
Saumya Srivastava
 
Immune check point inhibitors and adverse effects
Immune check point inhibitors and adverse effectsImmune check point inhibitors and adverse effects
Immune check point inhibitors and adverse effects
SCGH ED CME
 
Biological response modifiers
Biological response modifiersBiological response modifiers
Biological response modifiers
jireankita
 
Targeted cancer therapy
Targeted cancer therapy Targeted cancer therapy
Targeted cancer therapy
amarjeet singh
 
Overview and classification of chemotherapeutic agents and theory
Overview and classification of  chemotherapeutic agents and theoryOverview and classification of  chemotherapeutic agents and theory
Overview and classification of chemotherapeutic agents and theory
Saurabh Gupta
 
Immunotherapy ppt
Immunotherapy pptImmunotherapy ppt
Immunotherapy ppt
Kashikant Yadav
 
Gvhd
GvhdGvhd
Gvhd
joannayeh
 
Cancer immunotherapy
Cancer immunotherapyCancer immunotherapy
Cancer immunotherapy
Neha Patel
 
Targeted cancer therapies
Targeted cancer therapiesTargeted cancer therapies
Targeted cancer therapies
Dr. POOJA VAIDYA
 
Cancer Immunotherapy
Cancer ImmunotherapyCancer Immunotherapy
Cancer Immunotherapy
Pranav Sopory
 
Febrile neutropenia
Febrile neutropeniaFebrile neutropenia
Febrile neutropenia
ajayyadav753
 
Anthracyclines dr. varun
Anthracyclines dr. varunAnthracyclines dr. varun
Anthracyclines dr. varun
Varun Goel
 
Transplantation immunology
Transplantation immunology Transplantation immunology
Transplantation immunology
Kannan Iyanar
 
Guidelines of febrile neutropenia
Guidelines of febrile neutropeniaGuidelines of febrile neutropenia
Guidelines of febrile neutropenia
Marwa Khalifa
 
Immunotherapy
ImmunotherapyImmunotherapy
Immunotherapy
DrVasant Goswami
 

What's hot (20)

Stem cell transplantation
Stem cell transplantationStem cell transplantation
Stem cell transplantation
 
Immunotherapy for cancer
Immunotherapy for cancerImmunotherapy for cancer
Immunotherapy for cancer
 
Hsct copy
Hsct   copyHsct   copy
Hsct copy
 
Targeted Therapies in Cancer
Targeted Therapies in CancerTargeted Therapies in Cancer
Targeted Therapies in Cancer
 
Anthracyclines
Anthracyclines Anthracyclines
Anthracyclines
 
Stem cell transplant
Stem cell transplantStem cell transplant
Stem cell transplant
 
Immune check point inhibitors and adverse effects
Immune check point inhibitors and adverse effectsImmune check point inhibitors and adverse effects
Immune check point inhibitors and adverse effects
 
Biological response modifiers
Biological response modifiersBiological response modifiers
Biological response modifiers
 
Targeted cancer therapy
Targeted cancer therapy Targeted cancer therapy
Targeted cancer therapy
 
Overview and classification of chemotherapeutic agents and theory
Overview and classification of  chemotherapeutic agents and theoryOverview and classification of  chemotherapeutic agents and theory
Overview and classification of chemotherapeutic agents and theory
 
Immunotherapy ppt
Immunotherapy pptImmunotherapy ppt
Immunotherapy ppt
 
Gvhd
GvhdGvhd
Gvhd
 
Cancer immunotherapy
Cancer immunotherapyCancer immunotherapy
Cancer immunotherapy
 
Targeted cancer therapies
Targeted cancer therapiesTargeted cancer therapies
Targeted cancer therapies
 
Cancer Immunotherapy
Cancer ImmunotherapyCancer Immunotherapy
Cancer Immunotherapy
 
Febrile neutropenia
Febrile neutropeniaFebrile neutropenia
Febrile neutropenia
 
Anthracyclines dr. varun
Anthracyclines dr. varunAnthracyclines dr. varun
Anthracyclines dr. varun
 
Transplantation immunology
Transplantation immunology Transplantation immunology
Transplantation immunology
 
Guidelines of febrile neutropenia
Guidelines of febrile neutropeniaGuidelines of febrile neutropenia
Guidelines of febrile neutropenia
 
Immunotherapy
ImmunotherapyImmunotherapy
Immunotherapy
 

Viewers also liked

Acute graft versus host disease by dr. qutaiba abdulah
Acute graft versus host disease by  dr. qutaiba abdulahAcute graft versus host disease by  dr. qutaiba abdulah
Acute graft versus host disease by dr. qutaiba abdulah
Dr. Qutaiba Abdulah
 
Enfermedad injerto contra huesped por trasplante de medula
Enfermedad injerto contra huesped por trasplante de medulaEnfermedad injerto contra huesped por trasplante de medula
Enfermedad injerto contra huesped por trasplante de medula
Rosmary Hidalgo
 
plasmapheresis WHY WHEN AND HOW
 plasmapheresis WHY WHEN AND HOW  plasmapheresis WHY WHEN AND HOW
plasmapheresis WHY WHEN AND HOW
Ayman Seddik
 
Plasmapheresis
PlasmapheresisPlasmapheresis
Plasmapheresis
IPMS- KMU KPK PAKISTAN
 
Skin lesion in neonate
Skin lesion in neonateSkin lesion in neonate
Skin lesion in neonate
Loveis1able Khumpuangdee
 
Plasmapheresis
PlasmapheresisPlasmapheresis
Plasmapheresis
Amna Jalil
 
Humoral Immunity Lecture
Humoral Immunity LectureHumoral Immunity Lecture
Humoral Immunity Lecture
MD Specialclass
 
Enfermedad de injerto contra huésped
Enfermedad de injerto contra huéspedEnfermedad de injerto contra huésped
Enfermedad de injerto contra huésped
Layla Hernandez
 
Lanzamiento vertical hacia arriba
Lanzamiento vertical hacia arribaLanzamiento vertical hacia arriba
Lanzamiento vertical hacia arriba
Johan Guerra
 
Primary immunodeficiency
Primary immunodeficiencyPrimary immunodeficiency
Primary immunodeficiency
Nishitha Ashok
 
Humoral immune response
Humoral immune responseHumoral immune response
Humoral immune response
sufihannan
 
Bronchopulmonary segments
Bronchopulmonary segmentsBronchopulmonary segments
Bronchopulmonary segments
Rukiga District
 
14 Primary Immunodeficiency Diseases
14 Primary Immunodeficiency  Diseases14 Primary Immunodeficiency  Diseases
14 Primary Immunodeficiency Diseases
ghalan
 
Counselling HIV/ AIDS patient
Counselling HIV/ AIDS patient Counselling HIV/ AIDS patient
Counselling HIV/ AIDS patient
Qurrot Ulain Taher
 
Bronchopulmonary segments
Bronchopulmonary segmentsBronchopulmonary segments
Bronchopulmonary segments
Manjari Mishra
 
Genetic disorders
Genetic  disordersGenetic  disorders
Genetic disorders
Abdelrahman Mosaad
 
Hypersensitivity reactions
Hypersensitivity  reactions Hypersensitivity  reactions
Hypersensitivity reactions
Carmela Domocmat
 
Nursing Powerpoint Presentation
Nursing Powerpoint PresentationNursing Powerpoint Presentation
Nursing Powerpoint Presentation
Johannsen Baculio
 
Hypersensitivity
HypersensitivityHypersensitivity
Hypersensitivity
MD Specialclass
 
Gout presentation
Gout presentationGout presentation
Gout presentation
Kochi Chia
 

Viewers also liked (20)

Acute graft versus host disease by dr. qutaiba abdulah
Acute graft versus host disease by  dr. qutaiba abdulahAcute graft versus host disease by  dr. qutaiba abdulah
Acute graft versus host disease by dr. qutaiba abdulah
 
Enfermedad injerto contra huesped por trasplante de medula
Enfermedad injerto contra huesped por trasplante de medulaEnfermedad injerto contra huesped por trasplante de medula
Enfermedad injerto contra huesped por trasplante de medula
 
plasmapheresis WHY WHEN AND HOW
 plasmapheresis WHY WHEN AND HOW  plasmapheresis WHY WHEN AND HOW
plasmapheresis WHY WHEN AND HOW
 
Plasmapheresis
PlasmapheresisPlasmapheresis
Plasmapheresis
 
Skin lesion in neonate
Skin lesion in neonateSkin lesion in neonate
Skin lesion in neonate
 
Plasmapheresis
PlasmapheresisPlasmapheresis
Plasmapheresis
 
Humoral Immunity Lecture
Humoral Immunity LectureHumoral Immunity Lecture
Humoral Immunity Lecture
 
Enfermedad de injerto contra huésped
Enfermedad de injerto contra huéspedEnfermedad de injerto contra huésped
Enfermedad de injerto contra huésped
 
Lanzamiento vertical hacia arriba
Lanzamiento vertical hacia arribaLanzamiento vertical hacia arriba
Lanzamiento vertical hacia arriba
 
Primary immunodeficiency
Primary immunodeficiencyPrimary immunodeficiency
Primary immunodeficiency
 
Humoral immune response
Humoral immune responseHumoral immune response
Humoral immune response
 
Bronchopulmonary segments
Bronchopulmonary segmentsBronchopulmonary segments
Bronchopulmonary segments
 
14 Primary Immunodeficiency Diseases
14 Primary Immunodeficiency  Diseases14 Primary Immunodeficiency  Diseases
14 Primary Immunodeficiency Diseases
 
Counselling HIV/ AIDS patient
Counselling HIV/ AIDS patient Counselling HIV/ AIDS patient
Counselling HIV/ AIDS patient
 
Bronchopulmonary segments
Bronchopulmonary segmentsBronchopulmonary segments
Bronchopulmonary segments
 
Genetic disorders
Genetic  disordersGenetic  disorders
Genetic disorders
 
Hypersensitivity reactions
Hypersensitivity  reactions Hypersensitivity  reactions
Hypersensitivity reactions
 
Nursing Powerpoint Presentation
Nursing Powerpoint PresentationNursing Powerpoint Presentation
Nursing Powerpoint Presentation
 
Hypersensitivity
HypersensitivityHypersensitivity
Hypersensitivity
 
Gout presentation
Gout presentationGout presentation
Gout presentation
 

Similar to Management of acute graft versus host disease

Peri operative management of diabetes patients
Peri operative management of diabetes patientsPeri operative management of diabetes patients
Peri operative management of diabetes patients
Mahmoud Ibrahim
 
Treatment of chronic inflammatory demyelinating polyneuropathy
Treatment of chronic inflammatory demyelinating polyneuropathyTreatment of chronic inflammatory demyelinating polyneuropathy
Treatment of chronic inflammatory demyelinating polyneuropathy
MohamadAlhes
 
Treatment of recurrent and resistant dermatomyositis and polymyositis in adults
Treatment of recurrent and resistant dermatomyositis and polymyositis in adultsTreatment of recurrent and resistant dermatomyositis and polymyositis in adults
Treatment of recurrent and resistant dermatomyositis and polymyositis in adults
Mansoura university Hospital
 
Uses of Rituximab in Nephrology
Uses of Rituximab in Nephrology Uses of Rituximab in Nephrology
Uses of Rituximab in Nephrology
Mohammed Ahmed
 
Treatment of resistant & relapsing polymyositis dm
Treatment of  resistant & relapsing polymyositis dmTreatment of  resistant & relapsing polymyositis dm
Treatment of resistant & relapsing polymyositis dm
Faculty of Medicine, Ain Shams University
 
nephrotic syndrome.pptx
nephrotic syndrome.pptxnephrotic syndrome.pptx
nephrotic syndrome.pptx
ShamiPokhrel2
 
Clinically Isolated syndrome.pptx
Clinically Isolated syndrome.pptxClinically Isolated syndrome.pptx
Clinically Isolated syndrome.pptx
Mohamed AbdElhady
 
indolent lymphomas
indolent lymphomasindolent lymphomas
indolent lymphomas
Arnab Bose
 
Mg mangement guidelines
Mg mangement guidelinesMg mangement guidelines
Mg mangement guidelines
NeurologyKota
 
Durvalumab & urothelial carcinoma
Durvalumab & urothelial carcinomaDurvalumab & urothelial carcinoma
Durvalumab & urothelial carcinoma
Dr.Shreya Lal
 
Case Report on Invasive Mole. Gestational Trophoblastic Neoplasia (GTN) encom...
Case Report on Invasive Mole. Gestational Trophoblastic Neoplasia (GTN) encom...Case Report on Invasive Mole. Gestational Trophoblastic Neoplasia (GTN) encom...
Case Report on Invasive Mole. Gestational Trophoblastic Neoplasia (GTN) encom...
Niranjan Chavan
 
Vai trò của thuốc kháng virus trong đại dịch Covid 19
Vai trò của thuốc kháng virus trong đại dịch Covid 19Vai trò của thuốc kháng virus trong đại dịch Covid 19
Vai trò của thuốc kháng virus trong đại dịch Covid 19
EfenPhamNgoc
 
thyrotoxicosis in surgical view, thyroid surgery, including techniques, compl...
thyrotoxicosis in surgical view, thyroid surgery, including techniques, compl...thyrotoxicosis in surgical view, thyroid surgery, including techniques, compl...
thyrotoxicosis in surgical view, thyroid surgery, including techniques, compl...
Muhammad Khoshkani
 
Prophylaxis and treatment of opportunistic infections in HIV patients - Toxop...
Prophylaxis and treatment of opportunistic infections in HIV patients - Toxop...Prophylaxis and treatment of opportunistic infections in HIV patients - Toxop...
Prophylaxis and treatment of opportunistic infections in HIV patients - Toxop...
King Abdualziz Medical City -National Guard Health Affairs
 
Prophylaxis and treatment of opportunistic infections in HIV patients
Prophylaxis and treatment of opportunistic infections in HIV patientsProphylaxis and treatment of opportunistic infections in HIV patients
Prophylaxis and treatment of opportunistic infections in HIV patients
King Abdualziz Medical City -National Guard Health Affairs
 
anti TB and othes.pptx
anti TB and othes.pptxanti TB and othes.pptx
anti TB and othes.pptx
DerejeTsegaye8
 
PUD.pptx
PUD.pptxPUD.pptx
PUD.pptx
kamal uddin
 
Immunosupression in liver transplant.
Immunosupression in liver transplant.Immunosupression in liver transplant.
Immunosupression in liver transplant.
Dr. Thakur Prashant Singh
 
Bendamustine HCl for Injection Taj Pharma SmPC
Bendamustine HCl for Injection Taj Pharma SmPCBendamustine HCl for Injection Taj Pharma SmPC
Bendamustine HCl for Injection Taj Pharma SmPC
TajPharmaQC
 
A Glimpse at Precision Medicine in AML.
A Glimpse at Precision Medicine in AML.A Glimpse at Precision Medicine in AML.
A Glimpse at Precision Medicine in AML.
MarwaGamaleldin1
 

Similar to Management of acute graft versus host disease (20)

Peri operative management of diabetes patients
Peri operative management of diabetes patientsPeri operative management of diabetes patients
Peri operative management of diabetes patients
 
Treatment of chronic inflammatory demyelinating polyneuropathy
Treatment of chronic inflammatory demyelinating polyneuropathyTreatment of chronic inflammatory demyelinating polyneuropathy
Treatment of chronic inflammatory demyelinating polyneuropathy
 
Treatment of recurrent and resistant dermatomyositis and polymyositis in adults
Treatment of recurrent and resistant dermatomyositis and polymyositis in adultsTreatment of recurrent and resistant dermatomyositis and polymyositis in adults
Treatment of recurrent and resistant dermatomyositis and polymyositis in adults
 
Uses of Rituximab in Nephrology
Uses of Rituximab in Nephrology Uses of Rituximab in Nephrology
Uses of Rituximab in Nephrology
 
Treatment of resistant & relapsing polymyositis dm
Treatment of  resistant & relapsing polymyositis dmTreatment of  resistant & relapsing polymyositis dm
Treatment of resistant & relapsing polymyositis dm
 
nephrotic syndrome.pptx
nephrotic syndrome.pptxnephrotic syndrome.pptx
nephrotic syndrome.pptx
 
Clinically Isolated syndrome.pptx
Clinically Isolated syndrome.pptxClinically Isolated syndrome.pptx
Clinically Isolated syndrome.pptx
 
indolent lymphomas
indolent lymphomasindolent lymphomas
indolent lymphomas
 
Mg mangement guidelines
Mg mangement guidelinesMg mangement guidelines
Mg mangement guidelines
 
Durvalumab & urothelial carcinoma
Durvalumab & urothelial carcinomaDurvalumab & urothelial carcinoma
Durvalumab & urothelial carcinoma
 
Case Report on Invasive Mole. Gestational Trophoblastic Neoplasia (GTN) encom...
Case Report on Invasive Mole. Gestational Trophoblastic Neoplasia (GTN) encom...Case Report on Invasive Mole. Gestational Trophoblastic Neoplasia (GTN) encom...
Case Report on Invasive Mole. Gestational Trophoblastic Neoplasia (GTN) encom...
 
Vai trò của thuốc kháng virus trong đại dịch Covid 19
Vai trò của thuốc kháng virus trong đại dịch Covid 19Vai trò của thuốc kháng virus trong đại dịch Covid 19
Vai trò của thuốc kháng virus trong đại dịch Covid 19
 
thyrotoxicosis in surgical view, thyroid surgery, including techniques, compl...
thyrotoxicosis in surgical view, thyroid surgery, including techniques, compl...thyrotoxicosis in surgical view, thyroid surgery, including techniques, compl...
thyrotoxicosis in surgical view, thyroid surgery, including techniques, compl...
 
Prophylaxis and treatment of opportunistic infections in HIV patients - Toxop...
Prophylaxis and treatment of opportunistic infections in HIV patients - Toxop...Prophylaxis and treatment of opportunistic infections in HIV patients - Toxop...
Prophylaxis and treatment of opportunistic infections in HIV patients - Toxop...
 
Prophylaxis and treatment of opportunistic infections in HIV patients
Prophylaxis and treatment of opportunistic infections in HIV patientsProphylaxis and treatment of opportunistic infections in HIV patients
Prophylaxis and treatment of opportunistic infections in HIV patients
 
anti TB and othes.pptx
anti TB and othes.pptxanti TB and othes.pptx
anti TB and othes.pptx
 
PUD.pptx
PUD.pptxPUD.pptx
PUD.pptx
 
Immunosupression in liver transplant.
Immunosupression in liver transplant.Immunosupression in liver transplant.
Immunosupression in liver transplant.
 
Bendamustine HCl for Injection Taj Pharma SmPC
Bendamustine HCl for Injection Taj Pharma SmPCBendamustine HCl for Injection Taj Pharma SmPC
Bendamustine HCl for Injection Taj Pharma SmPC
 
A Glimpse at Precision Medicine in AML.
A Glimpse at Precision Medicine in AML.A Glimpse at Precision Medicine in AML.
A Glimpse at Precision Medicine in AML.
 

Recently uploaded

Allopurinol (Anti-gout drug).pptx
Allopurinol (Anti-gout drug).pptxAllopurinol (Anti-gout drug).pptx
Allopurinol (Anti-gout drug).pptx
Madhumita Dixit
 
Pune Call Girls 7339748667 AVAILABLE HOT GIRLS AUNTY BOOK NOW
Pune Call Girls 7339748667 AVAILABLE HOT GIRLS AUNTY BOOK NOWPune Call Girls 7339748667 AVAILABLE HOT GIRLS AUNTY BOOK NOW
Pune Call Girls 7339748667 AVAILABLE HOT GIRLS AUNTY BOOK NOW
Get New Sim
 
Nutritional deficiency disorder in Child
Nutritional deficiency disorder in ChildNutritional deficiency disorder in Child
Nutritional deficiency disorder in Child
Bhavyakelawadiya
 
5 Effective Homeopathic Medicines for Irregular Periods
5 Effective Homeopathic Medicines for Irregular Periods5 Effective Homeopathic Medicines for Irregular Periods
5 Effective Homeopathic Medicines for Irregular Periods
Dr. Deepika's Homeopathy - Gaur City
 
Call Girls in Kolkata 💯Call Us 🔝 7374876321 🔝 💃 Top Class Call Girl Servic...
Call Girls in Kolkata   💯Call Us 🔝 7374876321 🔝 💃  Top Class Call Girl Servic...Call Girls in Kolkata   💯Call Us 🔝 7374876321 🔝 💃  Top Class Call Girl Servic...
Call Girls in Kolkata 💯Call Us 🔝 7374876321 🔝 💃 Top Class Call Girl Servic...
daljeetsingh9909
 
Supporting Patient-Centered Care in Generalized Pustular Psoriasis: Communica...
Supporting Patient-Centered Care in Generalized Pustular Psoriasis: Communica...Supporting Patient-Centered Care in Generalized Pustular Psoriasis: Communica...
Supporting Patient-Centered Care in Generalized Pustular Psoriasis: Communica...
PVI, PeerView Institute for Medical Education
 
Call Girl Pune 7339748667 Vip Call Girls Pune
Call Girl Pune 7339748667 Vip Call Girls PuneCall Girl Pune 7339748667 Vip Call Girls Pune
Call Girl Pune 7339748667 Vip Call Girls Pune
Mobile Problem
 
Applications of NMR in Protein Structure Prediction.pptx
Applications of NMR in Protein Structure Prediction.pptxApplications of NMR in Protein Structure Prediction.pptx
Applications of NMR in Protein Structure Prediction.pptx
Anagha R Anil
 
mortality & morbidity indicators of health .pptx
mortality & morbidity indicators of health .pptxmortality & morbidity indicators of health .pptx
mortality & morbidity indicators of health .pptx
swarnkarmadhu
 
Ageing, the Elderly, Gerontology and Public Health
Ageing, the Elderly, Gerontology and Public HealthAgeing, the Elderly, Gerontology and Public Health
Ageing, the Elderly, Gerontology and Public Health
phuakl
 
Nano-gold for Cancer Therapy chemistry investigatory project
Nano-gold for Cancer Therapy chemistry investigatory projectNano-gold for Cancer Therapy chemistry investigatory project
Nano-gold for Cancer Therapy chemistry investigatory project
SIVAVINAYAKPK
 
Breast cancer :hormonal discordance.pptx
Breast cancer :hormonal discordance.pptxBreast cancer :hormonal discordance.pptx
Breast cancer :hormonal discordance.pptx
Dr. Sumit KUMAR
 
All about shoulder Joint ..
All about shoulder Joint .. All about shoulder Joint ..
All about shoulder Joint ..
Aya Reyad
 
Public Health Lecture 4 Social Sciences and Public Health
Public Health Lecture 4 Social Sciences and Public HealthPublic Health Lecture 4 Social Sciences and Public Health
Public Health Lecture 4 Social Sciences and Public Health
phuakl
 
Hemodialysis: Chapter 6, Hemodialysis Adequacy and Dose - Dr.Gawad
Hemodialysis: Chapter 6, Hemodialysis Adequacy and Dose - Dr.GawadHemodialysis: Chapter 6, Hemodialysis Adequacy and Dose - Dr.Gawad
Hemodialysis: Chapter 6, Hemodialysis Adequacy and Dose - Dr.Gawad
NephroTube - Dr.Gawad
 
Call Girls Lucknow 9024918724 Vip Call Girls Lucknow
Call Girls Lucknow 9024918724 Vip Call Girls LucknowCall Girls Lucknow 9024918724 Vip Call Girls Lucknow
Call Girls Lucknow 9024918724 Vip Call Girls Lucknow
nandinirastogi03
 
Spontaneous Bacterial Peritonitis - Pathogenesis , Clinical Features & Manage...
Spontaneous Bacterial Peritonitis - Pathogenesis , Clinical Features & Manage...Spontaneous Bacterial Peritonitis - Pathogenesis , Clinical Features & Manage...
Spontaneous Bacterial Peritonitis - Pathogenesis , Clinical Features & Manage...
Jim Jacob Roy
 
Call Girls Electronic City 🥰 Bangalore Call Girl No Advance Book Now
Call Girls Electronic City 🥰 Bangalore Call Girl No Advance Book NowCall Girls Electronic City 🥰 Bangalore Call Girl No Advance Book Now
Call Girls Electronic City 🥰 Bangalore Call Girl No Advance Book Now
saftyhealth48
 
OSPE response physiology 1 st yesr mbbs.pptx
OSPE response physiology 1 st yesr mbbs.pptxOSPE response physiology 1 st yesr mbbs.pptx
OSPE response physiology 1 st yesr mbbs.pptx
5btvo
 
Storyboard on Acne-Innovative Learning-M. pharm. (2nd sem.) Cosmetics
Storyboard on Acne-Innovative Learning-M. pharm. (2nd sem.) CosmeticsStoryboard on Acne-Innovative Learning-M. pharm. (2nd sem.) Cosmetics
Storyboard on Acne-Innovative Learning-M. pharm. (2nd sem.) Cosmetics
MuskanShingari
 

Recently uploaded (20)

Allopurinol (Anti-gout drug).pptx
Allopurinol (Anti-gout drug).pptxAllopurinol (Anti-gout drug).pptx
Allopurinol (Anti-gout drug).pptx
 
Pune Call Girls 7339748667 AVAILABLE HOT GIRLS AUNTY BOOK NOW
Pune Call Girls 7339748667 AVAILABLE HOT GIRLS AUNTY BOOK NOWPune Call Girls 7339748667 AVAILABLE HOT GIRLS AUNTY BOOK NOW
Pune Call Girls 7339748667 AVAILABLE HOT GIRLS AUNTY BOOK NOW
 
Nutritional deficiency disorder in Child
Nutritional deficiency disorder in ChildNutritional deficiency disorder in Child
Nutritional deficiency disorder in Child
 
5 Effective Homeopathic Medicines for Irregular Periods
5 Effective Homeopathic Medicines for Irregular Periods5 Effective Homeopathic Medicines for Irregular Periods
5 Effective Homeopathic Medicines for Irregular Periods
 
Call Girls in Kolkata 💯Call Us 🔝 7374876321 🔝 💃 Top Class Call Girl Servic...
Call Girls in Kolkata   💯Call Us 🔝 7374876321 🔝 💃  Top Class Call Girl Servic...Call Girls in Kolkata   💯Call Us 🔝 7374876321 🔝 💃  Top Class Call Girl Servic...
Call Girls in Kolkata 💯Call Us 🔝 7374876321 🔝 💃 Top Class Call Girl Servic...
 
Supporting Patient-Centered Care in Generalized Pustular Psoriasis: Communica...
Supporting Patient-Centered Care in Generalized Pustular Psoriasis: Communica...Supporting Patient-Centered Care in Generalized Pustular Psoriasis: Communica...
Supporting Patient-Centered Care in Generalized Pustular Psoriasis: Communica...
 
Call Girl Pune 7339748667 Vip Call Girls Pune
Call Girl Pune 7339748667 Vip Call Girls PuneCall Girl Pune 7339748667 Vip Call Girls Pune
Call Girl Pune 7339748667 Vip Call Girls Pune
 
Applications of NMR in Protein Structure Prediction.pptx
Applications of NMR in Protein Structure Prediction.pptxApplications of NMR in Protein Structure Prediction.pptx
Applications of NMR in Protein Structure Prediction.pptx
 
mortality & morbidity indicators of health .pptx
mortality & morbidity indicators of health .pptxmortality & morbidity indicators of health .pptx
mortality & morbidity indicators of health .pptx
 
Ageing, the Elderly, Gerontology and Public Health
Ageing, the Elderly, Gerontology and Public HealthAgeing, the Elderly, Gerontology and Public Health
Ageing, the Elderly, Gerontology and Public Health
 
Nano-gold for Cancer Therapy chemistry investigatory project
Nano-gold for Cancer Therapy chemistry investigatory projectNano-gold for Cancer Therapy chemistry investigatory project
Nano-gold for Cancer Therapy chemistry investigatory project
 
Breast cancer :hormonal discordance.pptx
Breast cancer :hormonal discordance.pptxBreast cancer :hormonal discordance.pptx
Breast cancer :hormonal discordance.pptx
 
All about shoulder Joint ..
All about shoulder Joint .. All about shoulder Joint ..
All about shoulder Joint ..
 
Public Health Lecture 4 Social Sciences and Public Health
Public Health Lecture 4 Social Sciences and Public HealthPublic Health Lecture 4 Social Sciences and Public Health
Public Health Lecture 4 Social Sciences and Public Health
 
Hemodialysis: Chapter 6, Hemodialysis Adequacy and Dose - Dr.Gawad
Hemodialysis: Chapter 6, Hemodialysis Adequacy and Dose - Dr.GawadHemodialysis: Chapter 6, Hemodialysis Adequacy and Dose - Dr.Gawad
Hemodialysis: Chapter 6, Hemodialysis Adequacy and Dose - Dr.Gawad
 
Call Girls Lucknow 9024918724 Vip Call Girls Lucknow
Call Girls Lucknow 9024918724 Vip Call Girls LucknowCall Girls Lucknow 9024918724 Vip Call Girls Lucknow
Call Girls Lucknow 9024918724 Vip Call Girls Lucknow
 
Spontaneous Bacterial Peritonitis - Pathogenesis , Clinical Features & Manage...
Spontaneous Bacterial Peritonitis - Pathogenesis , Clinical Features & Manage...Spontaneous Bacterial Peritonitis - Pathogenesis , Clinical Features & Manage...
Spontaneous Bacterial Peritonitis - Pathogenesis , Clinical Features & Manage...
 
Call Girls Electronic City 🥰 Bangalore Call Girl No Advance Book Now
Call Girls Electronic City 🥰 Bangalore Call Girl No Advance Book NowCall Girls Electronic City 🥰 Bangalore Call Girl No Advance Book Now
Call Girls Electronic City 🥰 Bangalore Call Girl No Advance Book Now
 
OSPE response physiology 1 st yesr mbbs.pptx
OSPE response physiology 1 st yesr mbbs.pptxOSPE response physiology 1 st yesr mbbs.pptx
OSPE response physiology 1 st yesr mbbs.pptx
 
Storyboard on Acne-Innovative Learning-M. pharm. (2nd sem.) Cosmetics
Storyboard on Acne-Innovative Learning-M. pharm. (2nd sem.) CosmeticsStoryboard on Acne-Innovative Learning-M. pharm. (2nd sem.) Cosmetics
Storyboard on Acne-Innovative Learning-M. pharm. (2nd sem.) Cosmetics
 

Management of acute graft versus host disease

  • 1. MANAGEMENT OF ACUTE GRAFT VERSUS HOST DISEASE (GVHD) Mahmoud A. Hashim Ahmed Khalaf Visiting Students UAB School of Medicine Hem-Onc Department Bone Marrow Transplantation Unit
  • 2. DEFINITION  Multisystem Disorders due to immune reaction caused by transplanted cells from a non-identical donor (the graft) that recognize recipient cells (the host) as foreign, thus disease is caused in the recipient organs.  It can be fatal in up to 15% of HSCT recipients.
  • 4. CLASSIFICATION  Patients with GVHD are sub classified based upon the timing of presentation and the features present:  Classic acute GVHD  Cases present within 100 days of hematopoietic cell transplant (HCT).  Shows features of acute GVHD.  Diagnostic features of chronic GVHD are absent.  Persistent, recurrent, late onset acute GVHD  Cases present greater than 100 days post-HCT.  Shows features of acute GVHD.  Diagnostic features of chronic GVHD are absent.  Classic chronic GVHD  Cases may present at any time post-HCT.  Diagnostic features of chronic GVHD are present.  There are no features of acute GVHD.  Overlap syndrome “Acute on Chronic GVHD”  Cases may present at any time post-HCT .  Shows features of both chronic GVHD and acute GVHD.
  • 5. CLINICAL MANIFESTATIONS AND GRADING I. Maculopapular rash. “ 1st and most common symptom” II. GI Symptoms “ 2nd commonest symptoms”  Diarrhea with or without Abd. Pain.  Persistent nausea and/or emesis. III. Jaundice “Glucksberg Criteria”
  • 6. Overall Grading of Acute GVHD If Karnofsky Performance <30%, then Grade 4
  • 7. DIAGNOSES I. Clinical Evaluation The diagnosis of aGvHD is predominantly based on clinical findings. II. Histological Tests A. Skin Biopsy is important in absence of the classic symptoms.  Skin biopsy was not found to be useful in predicting severity of disease. B. Rectosigmoid Biopsy was found to be the most informative. C. Transjugular liver biopsy can show Endothelialitis, Lymphocytic infiltration of the portal area, pericholangitis and Bile duct obstruction. III. Imaging  upper GI endoscopy as well as lower endoscopic biopsy may show Luminal Dilatation and Thckening of small bowel wall. IV. Biomarkers  There are many candidate biomarkers but none are ready for clinical application.
  • 8. MANAGEMENT  The choice of initial therapy for patients with acute graft-verus-host disease (GVHD) depends upon : Overall grading of Acute GVHD. Grade 1 GVHD Management A. Topical steroids are the most commonly used skin-directed therapy for acute GVHD. B. Antihistamines may be used as supportive therapy for patients with pruritus. C. In Resistant grade 1 aGVHD, Topical Tacrolimus may be useful. D. Optimizing prophylactic agents When acute GVHD of any grade develops, to ensure a therapeutic level. For those no longer receiving prophylaxis, the prior prophylactic agent should be restarted again.
  • 9. GRADE 2-4 GVHD  Patients with grade 2-4 disease are likely to require addition of Systemic agents to achieve a response and Optimizing prophylactic calcineurin inhibitors agents. A. First Line of Treatment: Corticosteroids  Most centres used 2 mg/kg /day of methylprednisolone to be the standard primary dose.  Oral beclomethasone, a non- absorbable glucocorticoid, is added for most patients with GI involvement.  Topical steroids can be added for further control of Skin lesions.  Steroids are continued for several weeks in responders and then gradually tapered over a period of several months.  Patients who shows progression of disease by day 5 or non-response by day 7 are considered to have corticosteroid resistance.  Use of Steroids results in complete response rates ranging from 25 to 40 %.
  • 10. HOW TO TAPER THE STEROIDS AFTER INITIAL RESPONSE? Conclusion I. Tapering of steroid doses should begin as soon as GVHD manifestations show major improvement. II. Inappropriately rapid taper rates carry a risk of GVHD exacerbation or recurrence, while inappropriately slow taper rates increase the risk of steroid-related complications. III. Doses should be gradual reduced 0.2 mg/kg/day every 3–5 days, after prednisone doses are decreased to less than 20–30 mg/day, slower tapering rate is required.
  • 11. B. Second Line of Treatment:  Given in Patients who fail to respond to 2 mg/kg/day Methylprednisolone for 5 d or progressive symptoms after 72 h.  There is nostrong comparative data showing superior efficacy for any particular agent over others, so the choice of a second-line regimen should be guided by 1. Considerations of potential toxicity, interactions with other agents 2. Expense 3. The familiarity of the physician with the agent 4. The prior experience of the physician  Includes: 1. Mycophenolate mofetil (MMF) 2. Etanercept “ Anti TNF Antibodies” 3. Pentostatin 4. Sirolimus 5. Basiliximab 6. Extracorporeal Photopheresis
  • 12. I. MYCOPHENOLATE MOFETIL (MMF) Mechanism of Action: I. MMF is a prodrug of mycophenolic acid (MPA), an inhibitor of inosine monophosphate dehydrogenase (IMPDH).  This is the rate-limiting enzyme in de novo synthesis of guanosine nucleotides.  T- and B-lymphocytes are more dependent on this pathway than other cell types are. II. MPA can induce apoptosis of activated T-lymphocytes. III. MMF dose in Adults is 2 gm/kg/day.  Side Effects  Dose related Cytopenia and gastrointestinal toxicity.  Moderate High possibility of Viral reactivation.
  • 13. II. ETANERCEPT  A recombinant human TNF-alpha receptor fusion protein.  Given SC at a dose of 0.4 mg/kg per dose, Twice/ week. (maximum dose, 25 mg/week).  Mechanism  A purine analog, a potent inhibitor of adenosine deaminase.  T and NK Cells Death occurs due to accumulation of 2-deoxyadenosine 5-triphosphate.  Dose: 1.5 mg/m2 IV /day for three days.  Pentostatin should be used with caution in patients with renal insufficiency.  A 50 % dose reduction has been suggested for patients with an estimated creatinine clearance of 30 to 50 mL/min/1.73 m2 III. Pentostatin
  • 14. IV. SIROLIMUS (RAPAMYCIN)  Mechanism  Exerts its immunosuppressive effect through inhibition of mTOR.  Loading dose of 6 mg/m2 followed by a daily dose of 3 mg/m2 daily for 13 days .  At a dose of 4 -5 mg/m2 without a loading dose for 14 days.  Reversible cytopenia, hypertriglyceridemia, and nephrotoxicity (HUS) and neurotoxicity when combined with calcineurin inhibitors.  The use of Sirolimus has also been associated with sinusoidal obstruction syndrome (SOS) following conditioning regimens especially, Busulfan.  Mechanism  Humanized monoclonal antibodies directed against the interleukin-2 receptor leading to prevention of T- cell proliferation. V. BASILIXIMAB VI. DENILEUKIN DIFTITOX  Mechanism Recombinant fusion molecule of human IL-2 and diphtheria toxin that binds to the IL-2R-α and triggers apoptosis in activated T cells.
  • 15. VII.EXTRACORPOREAL PHOTOPHERESIS  Infusion of ultraviolet-A irradiated autologous peripheral lymphocytes which have been collected by apheresis and incubated with 8- methoxypsoralen.  ECP induces apoptosis of all leucocytes (including activatedn T- cells) within 24 h of return.  Several studies have suggested that ECP may have a role in the treatment of acute GVHD.  Better results are expected in patients with disease limited to the skin.  Side effects is mild including hypotension, fevers and reduced hemoglobin level.
  • 16. GvHD Diagnosing and Grading Grade 1 Topical steroid Grade 2-4 First Line Systemic steroids 2mg/kg/day Second Line CONCLUSION MMF Etanercept Pentostatin Sirolimus Extracorporeal Photopheresis BASILIXIMAB
  • 17. REFERENCES I. Advances in graft-versus-host disease biology and therapy,2013, Bruce R. Blazar, William J. Murphy, and Mehrdad Abedi http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3552454/ II. Diagnosis and management of acute graft-versus-host disease, 2012, Fiona L. Dignan et al. http://www.bcshguidelines.com/documents/bjh_9129_Rev_EV.pdf III. First and Second-Line Systemic Treatment of Acute Graft-versus- host Disease: Recommendations of the American Society of Blood and Marrow Transplantation, Paul J. Martin et al. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3404151/ IV. Management of Acute GVHD, Uptodate.com V. Extracorporeal photopheresis in the management of graft-versus- host disease, Bredeson C et al. http://www.ncbi.nlm.nih.gov/pubmed/24764713

Editor's Notes

  1. Steps of Transplantation : Conditioning Stem cell infusion Neutropenic Phase Engraftment Phase Post- Engraftment Phase Overall aGVHD cascade Initiation and maintenance of aGVHD has been conceptualized into 4 phases with feedback loops that self-sustain the process. Although the effect of conditioning phase in aGVHD is not absolutely necessary, in many of the models it activates APCs, via tissue destruction, and improve APC capacity. It also, through release of gut bacteria, PAMPS and chemokines, can activate cellular components of innate immune system that can participate in direct tissue damage and contribute in cytokine storm. Host hematopoietic APCs have perhaps the most important role in initiation of GVHD, but this may depend on the model and the potential role of recipient APCs as well host non-hematopoietic APCs should not be ignored. Following antigen presentation, a strong cytokine response is initiated, promoting greater antigen presentation and recruitment of Teffs, and innate immune cells further contributing to the inflammatory cytokine milieu. Finally, the Teff cells, NK cells, macrophages and pro-inflammatory cytokines (e.g. TNF-α), will result in end organ damage, clinically recognized as aGVHD in the skin, lung, gut and liver. The resulting tissue damage, if not treated, will further escalate the disease, spiraling up the process to higher and more severe stages of GVHD pathology, which is extremely difficult to control.
  2. Although initial definitions of acute GVHD required an onset of symptoms before 100 days post transplantation, the current National Institutes of Health (NIH) consensus criteria use clinical findings, rather than a set time period, to differentiate between acute and chronic GVHD. 
  3. Scale Index allows patients to be classified as to their functional impairment 40Disabled; requires special care and assistance. 30Severely disabled; hospital admission is indicated although death not imminent. 20Very sick; hospital admission necessary; active supportive treatment necessary. 10Moribund; fatal processes progressing rapidly. 0Dead
  4. Liver biopsy is poses a significant risk of major bleeding since most patients are thrombocytopenic at the time of presentation with GVHD. Transjugular liver biopsy is a safer alternative if it can be adequately performed.
  5. In Grade 1: No systemic Steroids is used.  the most common prophylaxis regimen is the combination of cyclosporine and methotrexate. The cyclosporine is administered to reach a therapeutic target concentration, which varies according to the time from transplantation. A target concentration of 200 to 300 mcg/L is used during the first three to four weeks post transplant; then, if there is no GVHD, the target concentration is decreased to 100 to 200 mcg/L until three months after transplantation, and then tapered further. Patients who develop GVHD of any grade should have their cyclosporine dose adjusted to ensure a therapeutic level
  6. The mechanism of prednisolone their effects may because of lympholytic effects and anti-inflammatory properties Gradual tapering is important to prevent a flare of GVHD. These efficacy and toxicity data suggested the use of mycophenolate plus glucocorticoids as the most promising combination
  7. Day 28 post initiation of treatment complete response rates for methylprednisolone plus either etanercept, or mycophenolate, or denileukin, or pentostatin were 26, 60, 53, and 38 %, respectively. 9 month overall survival rates for these four treatment regimens were 47, 64, 49, and 47 percent, respectively. Cumulative incidences of severe infection were 48, 44, 62, and 57 percent, respectively.
  8. Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease, 2008 by Department of peds in Michigan medical school Showed that : Patients treated with etanercept plus steroids were significantly more likely to attain complete remission (CR) after 28 days than those treated with steroids alone (69 versus 33 percent)